文献速递神经肌肉病

2型糖尿病患者多发性神经病变5年内的发生与进展

Development and Progression of Polyneuropathy Over 5 Years in Patients With Type 2 Diabetes.
PubMed 文献 · Neurology · 2024-07-15

这项5年观察性随访队列研究纳入新诊断2型糖尿病患者与年龄性别相近的无糖尿病对照,采用多伦多共识标准分类糖尿病多发性神经病变(DPN)。随访结束时确诊DPN比例由基线35.8%升至50.3%,基线可能DPN者中43.9%进展为确诊DPN;神经参数进展与基线腰围和甘油三酯较高相关,回退与基线HbA1c较低相关。

要点

  • 确诊DPN比例由基线35.8%升至随访时50.3%,基线可能DPN者43.9%进展为确诊DPN。
  • 基于神经传导检查和表皮内神经纤维密度的进展率分别为16.5%和24.7%,回退率分别为5.9%和18.6%。
  • 神经参数进展与基线腰围和甘油三酯较高相关,回退与基线HbA1c较低相关。

核心结论

  • 在血糖控制良好的2型糖尿病患者中,5年内确诊DPN比例升高,主要由可能DPN向确诊DPN进展驱动。
  • 较大比例患者神经参数进展、较小比例回退,基线甘油三酯较高与进展相关,可能是危险因素。

研究设计与样本

  • 5年观察性随访队列研究,从全国队列招募新诊断2型糖尿病患者,并纳入年龄和性别相近的无糖尿病对照。
  • 基线于2016-2018年进行感觉表型评估,采用多伦多共识标准将患者分为可能、很可能和确诊DPN。
  • 随访复查结合床旁感觉检查、定量感觉测试(QST)、神经传导检查(NCS)和皮肤活检测量表皮内神经纤维密度(IENFD)。
  • 基线389例患者和97例对照中,184例患者和43例对照完成随访(46.9%)。

主要发现

  • 基线时确诊DPN占35.8%、很可能DPN占27.2%、可能DPN占17.2%、无DPN占15.2%;随访时分别为50.3%、14.6%、16.6%和17.9%。
  • 确诊DPN估计患病率(95%CI)由基线22.7%(17.5-28.0)升至33.5%(24.9-42.1)。
  • 随访期间,基线很可能DPN患者中43.9%进展为确诊DPN。
  • 基于NCS的神经病变进展率为16.5%、回退率为5.9%;基于IENFD的进展率为24.7%、回退率为18.6%。
  • 基于NCS和/或IENFD的进展与基线腰围和甘油三酯较高相关,回退与基线HbA1c较低相关。

关键数值与推荐

  • 采用多伦多共识标准将DPN分类为可能、很可能和确诊。
  • 基线184例完成随访患者的中位糖尿病病程为5.9年(四分位距4.1-7.4),基线平均HbA1c为51±11 mmol/mol。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: There is a need for knowledge regarding the natural course of diabetic polyneuropathy (DPN), a complication in type 2 diabetes (T2D). The aim of this study was to examine the development of DPN over time. METHODS: Patients with newly diagnosed T2D, recruited from a national cohort, and controls without diabetes of similar age and sex, underwent sensory phenotyping in 2016-2018. The Toronto consensus criteria were used to classify patients into possible, probable, and confirmed DPN. For this 5-year, observational, follow-up, cohort study, all participants were invited to a reexamination combining bedside sensory examination, quantitative sensory testing (QST), nerve conduction studies (NCSs), and skin biopsies measuring intraepidermal nerve fiber density (IENFD) in order to compare phenotypic and diagnostic changes over time. RESULTS: Of the baseline 389 patients and 97 controls, 184 patients (median [interquartile range] diabetes duration 5.9 [4.1-7.4] years, mean hemoglobin A1c [HbA1c] 51 ± 11 mmol/mol at baseline) and 43 controls completed follow-up (46.9%). Confirmed DPN was present in 35.8% and 50.3%, probable DPN in 27.2% and 14.6%, possible DPN in 17.2% and 16.6%, and no DPN in 15.2% and 17.9% at baseline and follow-up, respectively. The estimated prevalence (95% CI) of confirmed DPN was 33.5% (24.9-42.1) compared with 22.7% (17.5-28.0) at baseline. During the follow-up period, 43.9% of patients with probable DPN developed confirmed DPN. Progression of neuropathy occurred in 16.5% and 24.7% and regression in 5.9% and 18.6% of patients based on NCS and IENFD, respectively. Progression based on NCS and/or IENFD was associated with higher baseline waist circumference and triglycerides, and regression with lower baseline HbA1c. Patients with at least probable DPN at baseline but neither patients without DPN nor controls developed increased spread of hyposensitivity, more hyposensitivity on QST and lower NCS z-scores at follow-up, and worsening of nerve parameters at follow-up correlated with higher baseline triglycerides. DISCUSSION: In patients with well-regulated T2D, the proportion of patients with confirmed DPN increased over 5 years driven by progression from probable DPN. A large proportion of patients progressed, and a smaller proportion regressed on nerve parameters. Higher triglycerides correlated with this progression and may constitute a risk factor.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Brask-Thomsen PK, Itani M, Karlsson P, et al. Development and Progression of Polyneuropathy Over 5 Years in Patients With Type 2 Diabetes. Neurology. 2024. PMID: 39008800. doi:10.1212/WNL.0000000000209652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。